RNA interference - A silent but an efficient therapeutic tool

Applied Biochemistry and Biotechnology

Volumn 169, Issue 6, 2013, Pages 1774-1789

  Ramachandran, Puthucode Venkatakrishnan ^a   Ignacimuthu, Savarimuthu ^a  

^a LOYOLA COLLEGE   (India)

Author keywords

Cancer; Cardiovascular diseases; Diabetes mellitus; Gene silencing; MiRNA; Ocular diseases; RNAi; ShRNA; SiRNA; Therapeutic tool; Viral diseases

Indexed keywords

CANCER; CARDIO-VASCULAR DISEASE; DIABETES MELLITUS; GENE SILENCING; MIRNA; OCULAR DISEASE; RNAI; SHRNA; SIRNA; THERAPEUTIC TOOLS; VIRAL DISEASE;

DISEASES; GENE EXPRESSION; MOLECULAR BIOLOGY; RNA; TOOLS;

GENE THERAPY;

ATELOCOLLAGEN; BCR ABL PROTEIN; BETA CATENIN; CASPASE 2; CATHEPSIN B; DOXYCYCLINE; ECDYSONE; FAS ANTIBODY; GAG PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 21; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; NEF PROTEIN; REV PROTEIN; RNA BINDING PROTEIN EWS; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; TETRACYCLINE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR FLI 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; BONE DISEASE; CANCER GENE THERAPY; CANCER INHIBITION; CARDIOVASCULAR DISEASE; COLON CANCER; DIABETES MELLITUS; EYE DISEASE; FIBROSING ALVEOLITIS; GENE CASSETTE; GENE DELIVERY SYSTEM; GENE EXPRESSION SYSTEM; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEPATITIS; HUMAN; NONHUMAN; ONCOGENE; OSTEOARTHRITIS; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; VIRUS INFECTION; ANIMAL; GENETICS; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; GENETIC THERAPY; HUMANS; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84878581041     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-013-0098-1     Document Type: Article

References (143)

1. Hamilton, A. J., & Baulcombe, D. C. (1999). A species of small antisense RNA in post transcriptional gene silencing in plants. Science, 286, 950-952.
2. Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000). RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25-33.
3. Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409, 363-366.
4. Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001). RNA interference is mediated by 21- and 22- nucleotide RNAs. Genes & Development, 15, 188-200.
5. Sawh, A. N., & Duchaine, T. F. (2012). Turning Dicer on its head. Nature Structural and Molecular Biology, 19, 365-366.
6. Collins, R., & Cheng, X. (2005). Structural domains in RNAi. FEBS Letters, 579, 5841-5849.
7. Nykanen, A., Haley, B., & Zamore, P. D. (2001). ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell, 107, 309-321.
8. Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell, 115, 209-216.
9. Ahlquist, P. (2002). RNA-dependent RNA polymerases, viruses and RNAsilencing. Science, 296, 1270-1273.
10. Kwak, P. B., & Tomari, Y. (2012). The N domain of Argonaute drives duplex unwinding during RISC assembly. Nature Structural and Molecular Biology, 19, 145-152.
11. Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607-620.
12. Rand, T. A., Petersen, S., Du, F., &Wang, X. (2005). Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 123, 621-629.
13. Czech, B., & Hannon, G. J. (2011). Small RNA sorting: matchmaking for Argonautes. Nature Reviews Genetics, 12, 19-31.
14. Ghildiyal, M., & Zamore, P. D. (2009). Small silencing RNAs: an expanding universe. Nature Reviews Genetics, 10, 94-108.
15. Paul, C. P., Good, P. D., Winer, I., & Engelke, D. R. (2002). Effective expression of small interfering RNA in human cells. Nature Biotechnology, 20, 505-508.
16. Brummelkamp, T. R., Bernards, R., & Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550-553.
17. Kawasaki, H., & Taira, K. (2003). Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Research, 31, 700-707.
18. Borchert, G. M., Lanier, W., & Davidson, B. L. (2006). RNA polymerase III transcribes human microRNAs. Nature Structural and Molecular Biology, 13, 1097-1101.
19. Monteys, A. M., Spengler, R. M., Wan, J., Tecedor, L., Lennox, K. A., Xing, Y., & Davidson, B. L. (2010). Structure and activity of putative intronic miRNA promoters. RNA, 16, 495-505.
20. Ozsolak, F., Poling, L. L., Wang, Z., Liu, H., Liu, X. S., Roeder, R. G., Zhang, X., Song, J. S., & Fisher, D. E. (2008). Chromatin structure analyses identify miRNA promoters. Genes & Development, 22, 3172-3183.
21. Zeng, Y., Yi, R., & Cullen, B. (2005). Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO Journal, 24, 138-148.
22. Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim, S., & Kim, V. N. (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature, 425, 415-419.
23. Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & Shiekhattar, R. (2004). The microprocessor complex mediates the genesis of microRNAs. Nature, 432, 235-240.
24. Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004). Nuclear export of microRNA precursors. Science, 303, 95-98.
25. Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003). Exportin-5 mediates the nuclear export of premicroRNAs and short hairpin RNAs. Genes & Development, 17, 3011-3016.
26. Provost, P., Dishart, D., Doucet, J., Frendewey, D., Samuelsson, B., & Rådmark, O. (2002). Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO Journal, 21, 5864-5874.
27. Förstemann, K., Tomari, Y., Du, T., Vagin, V. V., Denli, A. M., Bratu, D. P., Klattenhoff, C., Theurkauf, W. E., & Zamore, P. D. (2005). Normal microRNA maturation and germ-line stem cell maintenance requires Loquacious, a double-stranded RNA-binding domain protein. PLoS Biology, 3, 1-15.
28. Hafner, M., Ascano, M., Jr., & Tuschl, T. (2011). New insights in the mechanism of microRNAmediated target repression. Nature Structural and Molecular Biology, 18, 1181-1182.
29. Kiriakidou, M., Tan, G. S., Lamprinaki, S., De Planell-Saguer, M., Nelson, P. T., & Mourelatos, Z. (2007). An mRNA m7G cap bindinglike motif within human Ago2 represses translation. Cell, 129, 1141-1151.
30. Chendrimada, T. P., Finn, K. J., Ji, X., Baillat, D., Gregory, R. I., Liebhaber, S. A., Pasquinelli, A. E., & Shiekhattar, R. (2007). MicroRNA silencing through RISC recruitment of eIF6. Nature, 447, 823-828.
31. Sorensen, D. R., Leirdal, M., & Sioud, M. (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. Journal of Molecular Biology, 327, 761-766.
32. Sioud, M., & Sorensen, D. R. (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochemical and Biophysical Research Communications, 312, 1220-1225.
33. Hamidreza, M., Abadi, A., Landry, B., Sun, C., Tang, T., & Uluda, H. (2012). Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials, 33, 2546-2569.
34. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Röhl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., & Vornlocher, H. P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
35. Song, E., Lee, S. K.,Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Medicine, 9, 347-351.
36. Van den Boorn, J. G., Schlee, M., Coch, C., & Hartmann, G. (2011). SiRNA delivery with exosome nanoparticles. Nature Biotechnology, 29, 325-326.
37. Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012). A review of nanocarriers for the delivery of small interfering RNA. Biomaterials, 33, 7138-7150.
38. Zhou, J., & Rossi, J. J. (2010). Aptamer-targeted cell-specific RNA interference. Silence, 4, 1-10.
39. McNamara, J. O. I. I., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnology, 24, 1005-1015.
40. Monaghan, M., & Pandit, A. (2011). RNA interference therapy via functionalized scaffolds. Advanced Drug Delivery Reviews, 63, 197-208.
41. Kulkarni, M., Greiser, U., O'Brien, T., & Pandit, A. (2010). Liposomal gene delivery mediated by tissueengineered scaffolds. Trends in Biotechnology, 28, 28-36.
42. De Laporte, L., & Shea, L. D. (2007). Matrices and scaffolds for DNA delivery in tissue engineering. Advanced Drug Delivery Reviews, 59, 292-307.
43. O'Rorke, S., Keeney, M., & Pandit, A. (2010). Non-viral polyplexes: scaffold mediated delivery for gene therapy. Progress in Polymer Science, 35, 441-458.
44. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., & Conklin, D. S. (2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes & Development, 16, 948-958.
45. Lee, N. S., Dohjima, T., Bauer, G., Li, H., Li, M. J., Ehsani, A., Salvaterra, P., & Rossi, J. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnology, 20, 500-505.
46. Sui, G., Soohoo, C., el Affar, B., Gay, F., Shi, Y., Forrester,W. C., & Shi, Y. (2002). A DNAvector-based RNAi technology to suppress gene expression in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 5515-5520.
47. Miyagishi, M., & Taira, K. (2002). U6 promoter driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nature Biotechnology, 20, 497-500.
48. Wang, S., & El-Deiry, W. S. (2004). Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Research, 64, 6666-6672.
49. Gupta, S., Schoer, R. A., Egan, J. E., Hannon, G. J., & Mittal, V. (2004). Inducible, reversible and stable RNA interference in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 101, 1927-1932.
50. Xia, H., Mao, Q., Paulson, H. L., & Davidson, B. L. (2002). siRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnology, 20, 1006-1010.
51. Chung, K. H., Hart, C. C., Al-Bassam, S., Avery, A., Taylor, J., Patel, P. D., Vojtek, A. B., & Turner, D. L. (2006). Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/ miR-155. Nucleic Acids Research, 34, e53.
52. Xia, X. G., Zhou, H., & Xu, Z. (2006). Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques, 41, 64-68.
53. Sun, D., Melegari, M., Sridhar, S., Rogler, C. E., & Zhu, L. (2006). Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques, 41, 59-63.
54. Hall, K., Blair Zajdel, M. E., & Blair, G. E. (2010). Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochemical Journal, 431, 321-336.
55. Li, H., Fu, X., Chen, Y., Hong, Y., Tan, Y., Cao, H., Wu, M., & Wang, H. (2005). Use of adenovirusdelivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology, 128, 2029-2041.
56. Osada, H., Tatematsu, Y., Yatabe, Y., Horio, Y., & Takahashi, T. (2005). ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Research, 65, 10680-10685.
57. Ragozin, S., Niemeier, A., Laatsch, A., Loeffler, B., Merkel, M., Beisiegel, U., & Heeren, J. (2005). Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1433-1438.
58. Schaser, T., Wrede, C., Duerner, L., Sliva, K., Cichutek, K., Schnierle, B., & Buchholz, C. J. (2011). RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors. Gene Therapy, 18, 953-960.
59. Matrai, J., Chuah, M. K., & VandenDriessche, T. (2010). Recent advances in lentiviral vector development and applications. Molecular Therapy, 18, 477-490.
60. Dittgen, T., Nimmerjahn, A., Komai, S., Licznerski, P., Waters, J., Margrie, T. W., Helmchen, F., Denk, W., Brecht, M., & Osten, P. (2004). Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proceedings of the National Academy of Sciences of the United States of America, 101, 18206-18211.
61. Bahi, A., Boyer, F., Kolira, M., & Dreyer, J. L. (2005). In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. Journal of Neurochemistry, 92, 1243-1255.
62. Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., Verma, I. M., & Masliah, E. (2005). Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nature Neuroscience, 8, 1343-1349.
63. Heilbronn, R., & Weger, S. (2010). Viral vectors for gene transfer: current status of gene therapeutics. Handbook of Experimental Pharmacology, 197, 143-170.
64. Grimm, D. (2009). Small silencing RNAs: state-of-the-art. Advanced Drug Delivery Reviews, 61, 672-703.
65. McCown, T. J. (2005). Adeno-associated virus (AAV) vectors in the CNS. Current Gene Therapy, 5, 333-338.
66. McLaughlin, J., Cheng, D., Singer, O., Lukacs, R. U., Radu, C. G., Verma, I. M., & Witte, O. N. (2007). Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proceedings of the National Academy of Sciences of the United States of America, 104, 20501-20506.
67. Radhakrishnan, S., Layden, T., & Gartel, A. (2004). RNA interference as a new strategy against viral hepatitis. Virology, 323, 173-181.
68. Brummelkamp, T. R., Bernards, R., & Agami, R. (2002). Stable suppression of tumorigenicity by virus mediated RNA interference. Cancer Cell, 2, 243-247.
69. Yang, G., Thompson, J., Fang, B., & Liu, J. (2003). Silencing of H-ras gene expression by retrovirusmediated siRNA decreases transformation efficiency and tumour growth in a model of human ovarian cancer. Oncogene, 22, 5694-5701.
70. Cioca, D., Aoki, Y., & Kiyosawa, K. (2003). RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Therapy, 10, 125-133.
71. Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002). Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proceedings of the National Academy of Sciences of the United States of America, 99, 14849-14854.
72. Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., & Muramatsu, T. (2004). A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Research, 64, 3365-3370.
73. Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, non viral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research, 65, 8984-8992.
74. Simmons, O., Maples, P. B., Senzer, N., & Nemunaitis, J. (2012). Ewing's sarcoma: development of RNA interference-based therapy for advanced disease. ISRN Oncology, 2012, 1-13.
75. Cui, Y., Wang, Q., Wang, J. Y., Dong, Y., Luo, C., Hu, G., & Lu, Y. (2012). Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells. Brain Research, 1469, 1-9.
76. Zhang, Z.,Wang, J., Shen, B., Peng, C., & Zheng, M. (2012). The ABCC4 gene is a promising target for pancreatic cancer therapy. Gene, 491, 94-199.
77. Zhou, W., Wang, L., Gou, S., Wang, T. L., Zhang, M., Liu, T., & Wang, C. (2012). ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Letters, 316, 178-186.
78. Hu, Y., Shen, Y., Baofang, J., Wang, L., Zhang, Z., & Zhang, Y. (2011). Combinational RNAi gene therapy of hepatocellular carcinoma by targeting human EGFR and TERT. European Journal of Pharmaceutical Sciences, 42, 387-391.
79. Mocellin, S., Costa, R., & Nitti, D. (2006). RNA interference: ready to silence cancer? Journal of Molecular Medicine (Berlin), 84, 4-15.
80. Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011). RNA interference and cancer therapy. Pharmaceutical Research, 28, 2983-2995.
81. Joost Haasnoot, P., Cupac, D., & Berkhout, B. (2003). Inhibition of virus replication by RNA interference. Journal of Biomedical Science, 10, 607-616.
82. McCaffrey, A., Nakai, H., Pandey, K., Huang, Z., Salazar, F., Xu, H., Wieland, S. F., Marion, P. L., & Kay, M. A. (2003). Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology, 21, 639-644.
83. Giladi, H., Ketzinel-Gilad, M., Rivkin, L., Felig, Y., Nussbaum, O., & Galun, E. (2003). Small interfering RNA inhibits hepatitis B virus replication in mice. Molecular Therapy, 8, 767-769.
84. Klein, C., Bock, C. T., Wedemeyer, H., Wüstefeld, T., Locarnini, S., Dienes, H. P., Kubicka, S., Manns, M. P., & Trautwein, C. (2003). Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology, 125, 9-18.
85. Shlomai, A., Lubelsky, Y., Har-Noy, O., & Shaul, Y. (2009). The "Trojan horse" model-delivery of anti- HBV small interfering RNAs by a recombinant HBV vector. Biochemical and Biophysical Research Communications, 390, 619-623.
86. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H., & Chen, J. (2004). Inhibition of influenza virus production in virus-infected mice by RNA interference. Proceedings of the National Academy of Sciences of the United States of America, 101, 88676-88681.
87. Merl, S., Michaelis, C., Jaschke, B., Vorpahl, M., Seidl, S., & Wessely, R. (2005). Targeting 2A protease by RNA interference attenuates coxsackie viral cytopathogenicity and promotes survival in highly susceptible mice. Circulation, 111, 1583-1592.
88. Devincenzo, J., Williams, R. L., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J., & Vaishnaw, A. (2010). A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. PNAS, 107, 8800-8805.
89. Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nature Medicine, 11, 50-55.
90. Blight, K. J., Kolykhalov, A. A., & Rice, C. M. (2000). Efficient initiation of HCV RNA replication in cell culture. Science, 290, 1972-1974.
91. Lohmann, V., Körner, F., Koch, J., Herian, U., Theilmann, L., & Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285, 110-113.
92. Ikeda, M., Yi, M., Li, K., & Lemon, S. M. (2002). Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. Journal of Virology, 76, 2997-3006.
93. Krieger, N., Lohmann, V., & Bartenschlager, R. (2001). Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. Journal of Virology, 75, 4614-4624.
94. Pietschmann, T., Lohmann, V., Rutter, G., Kurpanek, K., & Bartenschlager, R. (2001). Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. Journal of Virology, 75, 1252-1264.
95. Kishine, H., Sugiyama, K., Hijikata, M., Kato, N., Takahashi, H., Noshi, T., Nio, Y., Hosaka, M., Miyanari, Y., & Shimotohno, K. (2002). Subgenomic replicon derived from a cell line infected with the hepatitis C virus. Biochemical and Biophysical Research Communications, 293, 993-999.
96. McCaffrey, A. P., Meuse, L., Pham, T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A. (2002). RNA interference in adult mice. Nature, 418, 38-39.
97. Wilson, J. A., Jayasena, S., Khvorova, A., Sabatinos, S., Rodrigue-Gervais, I. G., Arya, S., Sarangi, F., Harris-Brandts, M., Beaulieu, S., & Richardson, C. D. (2003). RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 2783-2788.
98. Coburn, G. A., & Cullen, B. R. (2002). Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. Journal of Virology, 76, 9225-9331.
99. Surabhi, R. M., & Gaynor, R. B. (2002). RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. Journal of Virology, 76, 12963-12973.
100. Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J., Lee, S. K., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002). siRNA-directed inhibition of HIV-1 infection. Nature Medicine, 8, 681-686.
101. Park, W. S., Miyano-Kurosaki, N., Hayafune, M., Nakajima, E., Matsuzaki, T., Shimada, F., & Takaku, H. (2002). Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Research, 30, 4830-4835.
102. Jacque, J. M., Triques, K., & Stevenson, M. (2002). Modulation of HIV-1 replication by RNA interference. Nature, 418, 435-438.
103. Martinez, M. A., Gutierrez, A., Armand-Ugon, M., Blanco, J., Parera, M., Gomez, J., Clotet, B., & Esté, J. A. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS, 16, 2385-2390.
104. Capodici, J., Kariko, K., & Weissman, D. (2002). Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. Journal of Immunology, 169, 5196-5201.
105. Banerjea, A., Li, M. J., Bauer, G., Remling, L., Lee, N. S., Rossi, J., & Akkina, R. (2003). Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell derived macrophages. Molecular Therapy, 8, 62-71.
106. Li, M. J., Bauer, G., Michienzi, A., Yee, J. K., Lee, N. S., Kim, J., Li, S., Castanotto, D., Zaia, J., & Rossi, J. J. (2003). Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti- HIV RNAs. Molecular Therapy, 8, 196-206.
107. Boden, D., Pusch, O., Lee, F., Tucker, L., & Ramratnam, B. (2003). Human immunodeficiency virus type 1 escape from RNA interference. Journal of Virology, 77, 11531-11535.
108. Nevot, M., Martrus, G., Clotet, B., & Martínez, M. A. (2011). RNA interference as a tool for exploring HIV-1 robustness. Journal of Molecular Biology, 413, 84-96.
109. Ng, E. W., & Adamis, A. (2005). Targeting angiogenesis, the underlying disorder in neovascular agerelated macular degeneration. Canadian Journal of Ophthalmology, 40, 352-368.
110. Yuan, M. K., Tao, Y., Yu, W. Z., Kai, W., & Jiang, Y. R. (2010). Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularisation. Molecular Vision, 16, 1743-1753.
111. Reich, S. J., Fosnot, J., Kuroki, A., Tang, W., Yang, X., Maguire, A. M., Bennett, J., & Tolentino, M. J. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Molecular Vision, 9, 210-216.
112. Kim, B., Tang, Q., Biswas, P. S., Xu, J., Schiffelers, R. M., Xie, F. Y., Ansari, A. M., Scaria, P. V., Woodle, M. C., Lu, P., & Rouse, B. T. (2004). Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. American Journal of Pathology, 165, 2177-2185.
113. Check, E. (2005). A crucial test. Nature Medicine, 11, 243-244.
114. Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J., Yamasaki, S., Itaya, M., Pan, Y., Appukuttan, B., Gibbs, D., Yang, Z., Karikó, K., Ambati, B. K., Wilgus, T. A., DiPietro, L. A., Sakurai, E., Zhang, K., Smith, J. R., Taylor, E. W., & Ambati, J. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 452, 591-597.
115. Zwicky, R., Muntener, K., Goldring, M. B., & Baici, A. (2002). Cathepsin B expression and downregulation by gene silencing and antisense DNA in human chondrocytes. Biochemical Journal, 367, 209-217.
116. Kovar, H., Ban, J., & Pospisilova, S. (2003). Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Seminars in Cancer Biology, 13, 275-281.
117. Owen, L. A., & Lessnick, S. L. (2006). Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle, 5, 2049-2053.
118. Tomita, T., Takeuchi, E., Tomita, N., Morishita, R., Kaneko, M., Yamamoto, K., Nakase, T., Seki, H., Kato, K., Kaneda, Y., & Ochi, T. (1999). Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis and Rheumatism, 42, 2532-2542.
119. Roman-Blas, J. A., & Jimenez, S. A. (2006). NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage, 14, 839-848.
120. Schiffelers, R. M., Xu, J., Storm, G., Woodle, M. C., & Scaria, P. V. (2005). Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis and Rheumatism, 52, 1314-1318.
121. Wang, Y., & Grainger, D. W. (2012). RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Advanced Drug Delivery Reviews, 64, 1341-1357.
122. Barringhaus, K. G., & Zamore, P. D. (2009). MicroRNAs: regulating a change of heart. Circulation, 119, 2217-2224.
123. van Rooij, E., Sutherland, L. B., Liu, N.,Williams, A. H., McAnally, J., Gerard, R. D., Richardson, J. A., & Olson, E. N. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences of the United States of America, 103, 18255-18260.
124. Xu, T., Zhu, Y., Xiong, Y., Ge, Y. Y., Yun, J. P., & Zhuang, S. M. (2009). MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology, 50, 113-121.
125. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456, 980-984.
126. Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M. L., Segnalini, P., Gu, Y., Dalton, N. D., Elia, L., Latronico, M. V., Hoydal, M., Autore, C., Russo, M. A., Dorn, G. W., Ellingsen, O., Ruiz-Lozano, P., Peterson, K. L., Croce, C. M., Peschle, C., & Condorelli, G. (2007). MicroRNA- 133 controls cardiac hypertrophy. Nature Medicine, 13, 613-618.
127. Sayed, D., Hong, C., Chen, I. Y., Lypowy, J., & Abdellatif, M. (2007). MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Research, 100, 416-424.
128. Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., Chen, G., & Wang, Z. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nature Medicine, 13, 486-491.
129. Lynn, F. C., Skewes-Cox, P., Kosaka, Y., McManus, M. T., Harfe, B. D., & German, M. S. (2007). MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes, 56, 2938-2945.
130. El Ouaamari, A., Baroukh, N., Martens, G. A., Lebrun, P., Pipeleers, D., & Van Obberghen, E. (2008). MiR-375 targets 30-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes, 57, 2708-2717.
131. Herrera, B. M., Lockstone, H. E., Taylor, J. M., Wills, Q. F., Kaisaki, P. J., Barrett, A., Camps, C., Fernandez, C., Ragoussis, J., Gauguier, D., McCarthy, M. I., & Lindgren, C. M. (2009). MicroRNA- 125a is over-expressed in insulin target tissues in a spontaneous rat model of type 2 diabetes. BMC Medical Genomics, 2, 54.
132. Tang, X., Muniappan, L., Tang, G., & Ozcan, S. (2009). Identification of glucose regulated miRNAs from pancreatic beta cells reveals a role for miR-30d in insulin transcription. RNA, 15, 287-293.
133. Rehman, K. K., Trucco, M.,Wang, Z., Xiao, X., & Robbins, P. D. (2008). AAV8- mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Molecular Therapy, 16, 1409-1416.
134. Yau, W. W. Y., Rujitanaroj, P., Lam, L., & Chew, S. Y. (2012). Directing stem cell fate by controlled RNA interference. Biomaterials, 33, 2608-2628.
135. Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., Chi-Burris, K., Yan, E., Paggiarino, D. A., Rosenblatt, I., Khan, A., Aitchison, R., & Erlich, S. S. (2012). Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (London, England), 8, 1099-1105.
136. Ahmed, Z., Kalinski, H., Berry, M., Almasieh, M., Ashush, H., Slager, N., Brafman, A., Spivak, I., Prasad, N., Mett, I., Shalom, E., Alpert, E., Di Polo, A., Feinstein, E., & Logan, A. (2011). Ocular neuroprotection by siRNA targeting caspase-2. Cell Death and Diseases, 6, e173.
137. Verma, U. N., Surabhi, R. M., Schmaltieg, A., Becerra, C., & Gaynor, R. B. (2003). Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clinical Cancer Research, 4, 1291-1300.
138. Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. The Journal of Clinical Investigation, 119, 661-673.
139. Rahman, M. A., Amin, A. R., Wang, X., Zuckerman, J. E., Choi, C. H., Zhou, B., Wang, D., Nannapaneni, S., Koenig, L., Chen, Z., Chen, Z. G., Yen, Y., Davis, M. E., & Shin, D. M. (2012). Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. Journal of Controlled Release, 159, 384-392.
140. Strumberg, D., Schultheis, B., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J.,&Drevs, J. (2012). Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics, 50, 76-78.
141. Koldehoff, M., & Elmaagacli, A. H. (2009). Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Methods in Molecular Biology, 487, 451-466.
142. Dannull, J., Lesher, D. T., Holzknecht, R., Qi, W., Hanna, G., Seigler, H., Tyler, D. S., & Pruitt, S. K. (2007). Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood, 110, 4341-4350.
143. Astor, T. L. (2011). RNA interference, RSV, and lung transplantation: a promising future for siRNA therapeutics. American Journal of Respiratory and Critical Care Medicine, 183, 427-428.